BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 38372853)

  • 1. A Comprehensive Review of Cancer Drug-Induced Cardiotoxicity in Blood Cancer Patients: Current Perspectives and Therapeutic Strategies.
    Costanzo V; Ratre YK; Andretta E; Acharya R; Bhaskar LVKS; Verma HK
    Curr Treat Options Oncol; 2024 Apr; 25(4):465-495. PubMed ID: 38372853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.
    Lipshultz SE; Diamond MB; Franco VI; Aggarwal S; Leger K; Santos MV; Sallan SE; Chow EJ
    Paediatr Drugs; 2014 Oct; 16(5):373-89. PubMed ID: 25134924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic Aspects of Anthracycline Cardiotoxicity.
    Russo M; Della Sala A; Tocchetti CG; Porporato PE; Ghigo A
    Curr Treat Options Oncol; 2021 Feb; 22(2):18. PubMed ID: 33547494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guarding the heart: How SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity: SGLT-2 inhibitors and chemotherapy-induced cardiotoxicity.
    Vafa RG; Sabahizadeh A; Mofarrah R
    Curr Probl Cardiol; 2024 Mar; 49(3):102350. PubMed ID: 38128634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-induced cardiotoxicity in children.
    Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment and Management of Cardiotoxicity in Hematologic Malignancies.
    Bojan A; Torok-Vistai T; Parvu A
    Dis Markers; 2021; 2021():6616265. PubMed ID: 33613788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardio-oncology for Pediatric and Adolescent/Young Adult Patients.
    Tolani D; Wilcox J; Shyam S; Bansal N
    Curr Treat Options Oncol; 2023 Aug; 24(8):1052-1070. PubMed ID: 37296365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity of Contemporary Breast Cancer Treatments.
    Lee Chuy K; Yu AF
    Curr Treat Options Oncol; 2019 May; 20(6):51. PubMed ID: 31073788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Biomarkers to Evaluate Cardiotoxicity.
    Upshaw JN
    Curr Treat Options Oncol; 2020 Aug; 21(10):79. PubMed ID: 32767198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies to Prevent Cardiotoxicity.
    Graffagnino J; Kondapalli L; Arora G; Hawi R; Lenneman CG
    Curr Treat Options Oncol; 2020 Apr; 21(4):32. PubMed ID: 32270293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac complications in childhood cancer survivors treated with anthracyclines.
    Franco VI; Lipshultz SE
    Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension-Mechanisms and Mitigation.
    Butel-Simoes LE; Haw TJ; Williams T; Sritharan S; Gadre P; Herrmann SM; Herrmann J; Ngo DTM; Sverdlov AL
    Hypertension; 2023 Apr; 80(4):685-710. PubMed ID: 36756872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular Mechanisms Mediating Exercise-Induced Protection against Cardiotoxic Anthracycline Cancer Therapy.
    Dozic S; Howden EJ; Bell JR; Mellor KM; Delbridge LMD; Weeks KL
    Cells; 2023 May; 12(9):. PubMed ID: 37174712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthracycline-associated cardiotoxicity in survivors of childhood cancer.
    Trachtenberg BH; Landy DC; Franco VI; Henkel JM; Pearson EJ; Miller TL; Lipshultz SE
    Pediatr Cardiol; 2011 Mar; 32(3):342-53. PubMed ID: 21221562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart failure and chemotherapeutic agents.
    Piper S; McDonagh T
    Future Cardiol; 2015 Jul; 11(4):453-70. PubMed ID: 26234158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.
    Wu V
    J Pediatr Oncol Nurs; 2015; 32(3):178-84. PubMed ID: 25366577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying cancer patients at risk for cardiotoxicity.
    Salvatici M; Sandri MT
    Future Oncol; 2015; 11(14):2077-91. PubMed ID: 26198838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Management of cardiovascular complications secondary to medical treatment of cancer].
    Banke A; Polk A; Nielsen D; Videbæk L; Overgaard U; Fosbøl EL; Vaage-Nielsen M; Nielsen KM; Schou M
    Ugeskr Laeger; 2018 Feb; 180(7):. PubMed ID: 29465031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-induced cardiomyopathy.
    Higgins AY; O'Halloran TD; Chang JD
    Heart Fail Rev; 2015 Nov; 20(6):721-30. PubMed ID: 26338137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review.
    Madanat L; Gupta R; Weber P; Kumar N; Chandra R; Ahaneku H; Bansal Y; Anderson J; Bilolikar A; Jaiyesimi I
    Curr Cardiol Rev; 2023; 19(3):e310522205428. PubMed ID: 35642110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.